• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    PerkinElmer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    10/30/23 6:05:35 AM ET
    $PKI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PKI alert in real time by email
    falseREVVITY, INC.000003179100000317912023-10-302023-10-300000031791us-gaap:CommonStockMember2023-10-302023-10-300000031791pki:One875NotesDue2026Member2023-10-302023-10-30


     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     


    FORM 8-K
     

     
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): October 30, 2023

     


    Revvity, Inc.
    (Exact Name of Registrant as Specified in its Charter)


     
     
    Massachusetts
    001-05075
    04-2052042
    (State or Other Jurisdiction
    of Incorporation or Organization)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
     
    940 Winter Street, Waltham, Massachusetts
    02451
    (Address of Principal Executive Offices)
    (Zip Code)
     
    Registrant’s telephone number, including area code: (781) 663-6900
     
    Not applicable
    (Former Name or Former Address, if Changed Since Last Report)

     

     
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
      Trading Symbol(s)
      Name of exchange on which registered
    Common stock, $1 par value per share
     
    RVTY
     
    The New York Stock Exchange
    1.875% Notes due 2026
     
    RVTY 26
     
    The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company   ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




    Item 2.02.  Results of Operations and Financial Condition

    On October 30, 2023, Revvity, Inc. announced its financial results for the third quarter ended October 1, 2023.  The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
     
    Item 9.01.  Financial Statements and Exhibits

    (d)            Exhibits

      EXHIBIT INDEX
       
    Exhibit No.
    Description
     
     
    99.1*
    Press Release entitled “Revvity Announces Financial Results for the Third Quarter of 2023”, issued by Revvity, Inc. on October 30, 2023.
     
     
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL)

    * This exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed.

     
    SIGNATURE
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    REVVITY, INC.
    Date: October 30, 2023
    By: /s/ Maxwell Krakowiak
    Maxwell Krakowiak
    Senior Vice President and Chief Financial Officer

    Get the next $PKI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PKI

    DatePrice TargetRatingAnalyst
    12/19/2022$170.00Sector Weight → Overweight
    KeyBanc Capital Markets
    12/12/2022$135.00 → $170.00Neutral → Buy
    Citigroup
    12/6/2022$192.00 → $164.00Market Perform → Outperform
    Cowen
    11/28/2022$130.00 → $145.00Underweight → Equal Weight
    Barclays
    8/25/2022$175.00Neutral
    Credit Suisse
    8/18/2022$190.00 → $170.00Buy → Hold
    Stifel
    8/2/2022$178.00Buy → Neutral
    BofA Securities
    7/20/2022$160.00Buy
    UBS
    More analyst ratings